Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication of Renal Dialysis Clear all
Completed Phase 2 Interventional

Behavioral Intervention and Adherence in Dialysis

NCT01066949
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Behavioral self mangement, Support and discussion
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Dubuque, Iowa • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 3, 2026, 2:59 PM EDT
Terminated Not applicable Interventional

Functional Electrical Stimulation (FES) Exercise Training in Hemodialysis Patients

NCT01956214
View directory record Official record
Conditions
Complication of Dialysis
Interventions
FES Exercise, Mock FES Exercise
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
31 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Not applicable Interventional

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

NCT00477516
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
exposure to a high-calcium dialysate bath
Procedure
Lead sponsor
James B. Wetmore, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 2:59 PM EDT
Enrolling by invitation Not applicable Interventional

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Xeltis Hemodialysis Access (aXess) graft
Device
Lead sponsor
Xeltis
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 3, 2026, 2:59 PM EDT
Recruiting Not applicable Interventional

Symptom Monitoring in Hemodialysis

NCT05738330
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD), Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 3, 2026, 2:59 PM EDT
Enrolling by invitation No phase listed Observational

Feasibility of Intradialytic Monitoring During CKRT

NCT07428395
View directory record Official record
Conditions
Acute Kidney Injury, End Stage Chronic Renal Failure, Dialysis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Not applicable Interventional

Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

NCT00511225
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
cholecalciferol, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Not applicable Interventional

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

NCT06581393
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
Interventions
Moda-flx Hemodialysis System
Device
Lead sponsor
Diality Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ontario, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

NCT02975388
View directory record Official record
Conditions
Renal Impairment
Interventions
RO7079901
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 3, 2026, 2:59 PM EDT
Terminated Not applicable Interventional

ProStat Supplementation in Dialysis Patients

NCT00435123
View directory record Official record
Conditions
Malnutrition, ESRD
Interventions
Nutritional Supplement ProStat 64 twice a day, Placebo supplement
Dietary Supplement
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Wichita, Kansas • Springfield, Massachusetts • Columbus, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 3, 2026, 2:59 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01264679
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

NCT05745883
View directory record Official record
Conditions
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Lone Tree, Colorado • DeLand, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 3, 2026, 2:59 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
209
States / cities
Alexander City, Alabama • Birmingham, Alabama • Madison, Alabama + 177 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 3, 2026, 2:59 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

NCT03029208
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 3, 2026, 2:59 PM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Not applicable Interventional

The Measurement of Insulin Resistance in Peritoneal Dialysis Patients

NCT01119196
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Icodextrin dialysate
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 3, 2026, 2:59 PM EDT
Completed Phase 2 Interventional

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

NCT01305824
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 3, 2026, 2:59 PM EDT